SEC Form 4/A · accession 0001209191-17-064688
Dare Bioscience, Inc. · DARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
William H Rastetter
Director
Period of report
Jul 19, 2017
Accepted (ET)
Dec 8, 2017 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001401914
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2,F1,F3,F4 | $6.56 | Jul 19, 2017 | A | 2,000 | A | — | Jul 19, 2027 | Common Stock | 2,000 | 2,000 | D |
Explanation of responses
- F1The exercise price reported reflects the 10 for 1 reverse stock split effected by the Corporation on July 20, 2017.
- F2Dr. Rastetter was awarded options to purchase shares of the Corporation's common stock in connection with his service as a member of the Board of Directors (the "Director Options") pursuant to the Corporation's 2014 Stock Incentive Plan.
- F3This form amends a Form 4 previously filed for Dr. Rastetter on July 21, 2017, to correct the description of the vesting schedule of the stock options.
- F4The Director Options will vest in full on the earlier of the one year anniversary of the date of grant or immediately prior to the Corporation's 2018 annual meeting of stockholders.